A new urine-based clear cell renal cell carcinoma (ccRCC) recurrence test could reduce the number of CT scans needed to monitor patients with kidney cancer following surgery, as well as providing a “more comfortable alternative to post-operative monitoring.”
Sweden-based Elypta presented the results of the international AURORAX-0087A (AUR87A) study at the 2025 European Association of Urology Congress on 24 March
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?